Report cover image

US Cell & Gene Therapy Market - Focused Insights 2023-2028

Publisher Arizton Advisory and Intelligence
Published May 17, 2023
SKU # ARZ17949477

Description

US Cell & Gene Therapy Market - Focused Insights 2023-2028


REPORT OVERVIEW
  • This report offers market size & forecast data for the cell & gene therapy market in the US. The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies. Cell therapies sourced from mesenchymal stem cells, cell-based immune modulation therapies, and cell/tissue-based products derived from patients' blood are also covered in the report. Tissue-engineered products and tissue grafts/scaffolds with synthetic mechanical structures are excluded from the report's scope. This report provides a comprehensive and current market scenario of the US cell & gene therapy market, including the US cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023−2028 in the US. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.
MARKET DEFINITION


Cell and gene therapies are part of advanced therapy medicinal products (ATMPs) developed based on genes, tissues, and cells. The introduction of many novel ATMPs in recent years, especially cell and gene therapies, changed the treatment dynamics of many complex and challenging diseases like cancer and genetic disorders. In recent years, growth in the cell and gene therapy market has fueled some high-profile mergers and acquisitions, including bluebird bio/BioMarin, Bristol-Myers Squibb/Celgene/Juno Therapeutics, Gilead Sciences/Kite, Novartis/AveXis and the CDMO CELLforCURE, Roche/Spark Therapeutics, and Smith & Nephew/Osiris Therapeutics. Over 20 cell therapy launches and as many as 31 gene therapies launches—including more than 29 Adeno-associated viruses (AAV) therapies—are projected to be approved by 2024.

KEY HIGHLIGHTS
  • The US cell and gene therapy market was valued at $3.22 billion in 2022 and is projected to reach $25.58 billion in 2028, with a compound annual growth rate (CAGR) of 41.25%, during the study period.
  • Among all commercial cell & gene therapies, Zolgensma is the first and only product to achieve the blockbuster drug tag. Zolgensma generated a revenue of $1.37 billion in 2022 and could reach around $5.00 billion by 2026.
  • Drug developers are prioritizing developing and commercializing CAR-T cell-based gene therapies. Globally, more than 1,000 clinical trials are being conducted on CAR T-cell therapies, of which at least 500 clinical trials are for cancer alone. Kymriah (Novartis), Yescarta (Gilead Sciences), Tecartus (Gilead Sciences), Breyanzi (Bristol Myers Squibb), Abecma (Bristol Myers Squibb), and Carvykti (Janssen Biotech / Legend Biotech) are the commercial CAR-T therapies available in the market.
  • In 2022, the US was the fastest-growing market with a high market share in North America. The market is driven by an increased target patient population, regulatory body support, and higher access to healthcare due to well-established healthcare infrastructure.
  • The Food and Drug Administration (FDA) has approved over twenty cell and gene therapy drugs. Still, the new product pipeline has approximately 365 investigational therapies, with more than half of these in Phase 2 clinical trials. Oncology and rare diseases remain the top areas targeted by gene therapies from preclinical through pre-registration.
  • Approximately 1,604 clinical trials are under investigation for various cell and gene therapies in the US. This increase could be because of increased funding for cell and gene therapy. The industry-sponsored trials are continued to dominate with a share of 51.81%.
  • Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the US cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of a large pool of target patient populations with chronic diseases such as cancer, genetic and rare diseases, and other complex disorders.
VENDOR ANALYSIS
  • Novartis
  • Gilead Sciences
  • Amgen
  • Roche
  • bluebird bio
  • Legend Biotech
  • Bristol-Myers Squibb
  • UniQure
  • Ferring Pharmaceuticals
  • Organogenesis
  • Vericel Corp
  • Dendreon
  • Mallinckrodt
  • Enzyvant
  • Avita Medical
  • Fibrocell
  • 4DMT
  • Abeona Therapeutics
  • Autolus Therapeutics
  • Candel Therapeutics
  • Castel Creek Biosciences
  • Cellectis
  • Evox Therapeutics
  • Freeline Therapeutics
  • Generation Bio
  • Gensight Biologics
  • Krystal Biotech
  • MeiraGTx
  • Pfizer
  • Gamida Cell
  • Iovance Biotherapeutics
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Atara Bio
  • Adaptimmune
  • CRISPR Therapeutics
  • Carsgen Therapeutics
  • Orchard Therapeutics
  • Biomarin
  • StemCyte
  • Helixmith
REPORT HIGHLIGHTS

PRODUCT SEGMENTATION & FORECAST
  • Product type
  • Cell therapy
  • Gene therapy
  • Application type
  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others
  • End-user type
  • Hospitals
  • Cancer Care Centers
  • Others
MARKET STRUCTURE
  • Approved Cell & Gene Therapies
  • Pipeline Analysis
  • Clinical Trial Analysis
  • Market Dynamics
  • Competitive Landscape of Cell & Gene Therapies
  • Key Vendors
  • Other Prominent Vendors
PRICING & REIMBURSEMENT SCENARIO
  • Pricing, Reimbursement, and Market Access
  • Contract Manufacturing Organizations
APPENDIX
  • Research Methodology
  • Abbreviations
  • About Arizton

Table of Contents

CHAPTER – 1: Cell & Gene Therapy Market Overview
Executive Summary
Introduction
Key Findings
Key Developments
CHAPTER – 2: Cell & Gene Therapy Market Segmentation Data
US: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
Product type
Application type
End-user type
CHAPTER – 3: Cell & Gene Therapy Prospects & Opportunities
Cell & Gene Therapy Market Drivers
Cell & Gene Therapy Market Trends
Cell & Gene Therapy Market Constraints
CHAPTER – 4: Cell & Gene Therapy Industry Overview
Cell & Gene Therapy - Marketed Drugs Overview
Cell & Gene Therapy - Pipeline Drugs Overview
Cell & Gene Therapy - Competitive Landscape
Cell & Gene Therapy - Key Players
Cell & Gene Therapy - Key Company Profiles
Cell & Gene Therapy - Mergers & Acquisitions
Cell & Gene Therapy - Key Strategic Recommendations
CHAPTER – 5: Pricing and Reimbursement Scenario
Pricing, Reimbursement and Market Access
Contract Manufacturing Organizations (CMOs)
CHAPTER – 6: Appendix
Research Methodology
Abbreviations
About Arizton

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us